{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:57:44Z","timestamp":1792457864929,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014425","name":"Acorda Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clinthera.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T03:40:32Z","timestamp":1590810032000},"page":"1034-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease"],"prefix":"10.1016","volume":"42","author":[{"given":"Beth E.","family":"Safirstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Herbert R.","family":"Henney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena M.","family":"Kegler-Ebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.clinthera.2020.04.004_bib1","first-page":"S3","article-title":"Levodopa therapy for Parkinson disease: a look backward and forward","volume":"86","author":"LeWitt","year":"2016","journal-title":"Neurology"},{"issue":"Suppl 11","key":"10.1016\/j.clinthera.2020.04.004_bib2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","article-title":"The spectrum of \"off\" in Parkinson's disease: what have we learned over 40 years?","volume":"51","author":"Chou","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002826-198712000-00004","article-title":"Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients","volume":"10","author":"Baruzzi","year":"1987","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2020.04.004_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jnnp.52.Suppl.29","article-title":"The on-off phenomenon","author":"Lees","year":"1989","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2020.04.004_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","article-title":"The \"on-off\" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport","volume":"310","author":"Nutt","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.04.004_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11940-018-0539-9","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"20","author":"Pfeiffer","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinthera.2020.04.004_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14656566.7.10.1399","article-title":"The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations","volume":"7","author":"Stocchi","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2020.04.004_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.parkreldis.2019.03.026","article-title":"Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease","volume":"64","author":"Hauser","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib10","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/mds.26611","article-title":"A\u00a0randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease","volume":"31","author":"LeWitt","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","article-title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"18","author":"LeWitt","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2020.04.004_bib12","doi-asserted-by":"crossref","first-page":"360ra136","DOI":"10.1126\/scitranslmed.aad8858","article-title":"Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease","volume":"8","author":"Lipp","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2020.04.004_bib13","first-page":"157","article-title":"Inhaled levodopa (CVT-301) for treatment of OFF periods in Parkinson's disease: efficacy as assessed by 39-item Parkinson's disease quality of life questionnaire [abstract\/poster P23.10]. World Parkinson Congress: Kyoto, Japan, June 4\u20137, 2019","volume":"9","author":"LeWitt","year":"2019","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.clinthera.2020.04.004_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/17425255.2018.1550483","article-title":"Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease","volume":"14","author":"Stocchi","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2020.04.004_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40734-016-0036-9","article-title":"Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease","volume":"3","author":"Virmani","year":"2016","journal-title":"J\u00a0Clin Mov Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib16","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1038\/npjsba.2016.13","article-title":"Model-based dietary optimization for late-stage, levodopa-treated, Parkinson's disease patients","volume":"2","author":"Guebila","year":"2016","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.clinthera.2020.04.004_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fnagi.2017.00206","article-title":"Protein-restricted diets for ameliorating motor fluctuations in Parkinson's Disease","volume":"9","author":"Wang","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.clinthera.2020.04.004_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","article-title":"Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations","volume":"19","author":"Goetz","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/jamp.2016.1354","article-title":"Pulmonary safety and tolerability of inhaled levodopa (CVT-301) administered to patients with Parkinson's disease","volume":"31","author":"LeWitt","year":"2018","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.clinthera.2020.04.004_bib20","series-title":"Guidance for Industry: Statistical Approaches to Establishing Bioequivalence","year":"2001"},{"key":"10.1016\/j.clinthera.2020.04.004_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.parkreldis.2011.12.004","article-title":"Gastroparesis and Parkinson's disease: a systematic review","volume":"18","author":"Heetun","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mds.25708","article-title":"Delayed gastric emptying in Parkinson's disease","volume":"29","author":"Marrinan","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2020.04.004_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002826-200603000-00001","article-title":"Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients","volume":"29","author":"Muller","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2020.04.004_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","article-title":"Pharmacokinetics of levodopa","volume":"7","author":"Nutt","year":"1984","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2020.04.004_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/242463a0","article-title":"Active transport of L-dopa in the intestine","volume":"242","author":"Wade","year":"1973","journal-title":"Nature"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:48Z","timestamp":1758963108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820301909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0149291820301909"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.04.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}